Researchers found that people with newly diagnosed stage III or IV Hodgkin lymphoma with complete remission and negative scans after two ABVD regimen cycles, or PET2, who continued ABVD treatment and those with positive scans who switched to an escalated BEACOPP regimen had a 94% estimated five-year overall survival rate, but nearly 25% of those who were PET2-negative had a relapse. The findings in the journal Blood also showed that those who received eBEACOPP had a higher prevalence of secondary cancers, compared with those who were given ABVD.
PET-adapted treatment examined in advanced Hodgkin lymphoma
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.